The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

BACKGROUND: Second-line treatment for advanced non-small-cell lung cancer (NSCLC) patients includes monotherapy with a third-generation cytotoxic drug (CT) or a tyrosine kinase inhibitor (TKI). These options are the actual standard for EGFR wild-type (WT) status, as patients with EGFR mutations achi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Bronte, Giuseppe, Franchina, Tindara, Alù, Massimiliano, Sortino, Giovanni, Celesia, Claudia, Passiglia, Francesco, Savio, Giuseppina, Laudani, Agata, Russo, Alessandro, Picone, Antonio, Rizzo, Sergio, De Tursi, Michele, Gambale, Elisabetta, Bazan, Viviana, Natoli, Clara, Blasi, Livio, Adamo, Vincenzo, Russo, Antonio
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5094963/
https://ncbi.nlm.nih.gov/pubmed/26993607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8130
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires